Active, not recruitingPhase 2NCT02406222
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Leeds
- Principal Investigator
- Martin Kaiser, DrRoyal Marsden NHS Foundation Trust
- Intervention
- Pomalidomide(drug)
- Enrollment
- 124 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2025
Study locations (21)
- Belfast Health & Social Care Trust, Belfast, United Kingdom
- University of Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
- Royal Sussex County Hospital, Brighton, United Kingdom
- Queens Hospital, Burton-on-Trent, United Kingdom
- University Hospital of Wales NHS Trust, Cardiff, United Kingdom
- Ninewells Hospital, Dundee, United Kingdom
- Beatson Oncology Centre, Glasgow, United Kingdom
- St James's Hopsital, Leeds, United Kingdom
- University Hospital of Leicester NHS Trust, Leicester, United Kingdom
- St Bartholomew Hospital, London, United Kingdom
- University College London Hospital, London, United Kingdom
- Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
- The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Imperial College Hospital, London, United Kingdom
- +6 more locations on ClinicalTrials.gov
Collaborators
Myeloma UK · Celgene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02406222 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University